Why Oncologists Get Sued: Delayed Cancer Diagnosis and Chemotherapy Dosing Errors

By John Mahoney · June 2026 · 9 min read

Oncology is not on anyone's list of the most-sued specialties — and that is exactly why its claims are easy to underestimate. Hematology/oncology generates relatively few malpractice claims, only a minority of those claims pay, and the specialty is priced for low risk by insurers. But the cases that do mature are among the most expensive and emotionally charged in all of medical malpractice, because they involve a missed window to treat a curable cancer or a chemotherapy error that killed or maimed a patient already fighting for survival. This guide explains where oncology liability actually lives, the cannot-miss failures behind it, and what separates a strong case from a weak one — for plaintiff and defense med-mal attorneys alike.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. The figures below come from closed-claims and insurer datasets that span different eras and definitions; some oncology data falls below the reporting thresholds used for higher-volume specialties. Treat the numbers as directional, verify against the controlling jurisdiction, and value each case on its own record.

The Frequency-and-Severity Reality

By frequency, oncology runs low. It is among the lower-risk specialties — the Jena physician-malpractice analysis excluded oncology from its specialty table because it had fewer than 30 indemnity payments over the study window, itself a marker of low absolute claim volume against an all-specialty annual claim rate near 7.4%. Industry surveys put the share of oncologists ever named in a suit below the all-specialty figure, and oncology does not rank in the top tier of most-sued specialties. Hematology, on the non-malignant side, carries even lower procedural exposure and is generally folded into internal-medicine risk classes.

Severity is the opposite story. Reported mean indemnity for the specialty runs in the mid-$200,000s, with the median well below that — but the average hides the tail: in some closed-claims data about 13% of paid claims exceeded $1 million while half were under $100,000, and only roughly a quarter of claims resulted in any payment at all. Injury severity is high where it lands: in some series around 63% of claims involved high-severity injuries and 43% involved patient death. Delayed-cancer-diagnosis claims are among the most expensive in all of medical malpractice, because the damages model is a lost cure or a foreshortened life. This is the central screening lesson: oncology cannot be valued on per-claim averages; it is valued on the specific cancer, the lost window, and the prognosis at the time of the alleged failure.

The Dominant Allegation Types

Oncology claims fall into a tight cluster:

• Diagnosis-related — failure or delay in diagnosis — reported around 26–29% of closed claims. This is the high-indemnity heart of the specialty.
• Improper management of the treatment course — reported in a wide band, roughly 24–38%.
• Medication-related claims — chemotherapy dosing and administration errors and adverse drug reactions, reported around 15–29%. Medication-related allegations paid indemnity at a notably high rate in some data (reported around 52% of those claims).
• Informed-consent deficiencies.
• Failure to monitor or manage complications — neutropenia, tumor lysis, and, on the hematology side, anticoagulation management.

Two distinct liability stories live inside this list. The first is cognitive: a delayed or missed cancer diagnosis. The second is operational: a chemotherapy error in a high-stakes, narrow-therapeutic-index environment. They have different fact patterns, different experts, and different causation fights — and an intake should route on which one it is from the first conversation.

The Cannot-Miss Conditions and Failures

The severe end of oncology litigation is driven by a short list:

• Delayed or missed cancer diagnosis — breast, lung, and colorectal lead the classic high-indemnity "delayed-dx" cluster. The recurring fingerprint is an abnormal imaging, lab, or tumor-marker result that was not tracked to resolution, or a biopsy/staging that came too late.
• Chemotherapy dosing errors — overdose or underdose, narrow-therapeutic-index agents, body-surface-area miscalculations, wrong-drug or wrong-regimen, and infusion-rate or schedule errors.
• Adverse medication reactions — chemotherapy toxicity, extravasation, and neutropenic sepsis, a meaningful share of injuries in closed-claims data.
• Disease progression or metastasis from delayed or inappropriate treatment.
• Hematology-specific failures — anticoagulation-management errors, failure to diagnose a hematologic malignancy such as leukemia or lymphoma, transfusion-related events, and undertreated pain.

For the diagnostic cluster, the single most actionable screening question is the closed-loop question: was there an abnormal result — an imaging finding, a tumor marker, a positive screening test — that was never communicated, never acted on, or never tracked to a definitive diagnosis? That failure-to-close-the-loop pattern is both the most common systemic merit signal and the easiest to prove from the record.

The Contributing Factors That Drive Payouts

Across oncology closed claims the recurring contributing factors are:

• Clinical judgment — the largest single driver and the factor most strongly associated with adverse settlement outcomes, including inadequate patient assessment (reported around 33–38%) and inappropriate selection of therapy (reported around 47% in medication claims).
• Patient behavior / patient factors — notably high in oncology, reported around 52% in diagnosis-related claims (noncompliance, missed follow-up). This is a genuine defense lever where the record shows the patient drove the delay.
• Communication — among providers and between provider and patient/family, reported in roughly the 17–33% range, a non-clinical factor that grows as care fragments across offices and oral-agent regimens.
• Documentation and care-coordination/handoff gaps, increasingly important as chemotherapy moves off-site and onto oral agents.
• System factors — role overload, unclear orders, understaffing, and inadequate access to guidelines, prominent in nursing and administration-error studies.

The patient-behavior factor is worth dwelling on because it cuts both ways. A documented pattern of missed appointments, declined imaging, or non-adherence is one of the strongest defense facts in a delayed-diagnosis case — it attacks both breach and causation. Conversely, where the chart shows the patient did everything asked and the system lost the result, communication and documentation gaps that are usually defensibility levers become near-dispositive. Clinical judgment, recorded clearly, is what holds the defense together; its absence is what the plaintiff exploits.

Strong Case vs. Weak Case in Oncology

The same factors grade the file, and the framing is useful to both sides.

What makes an oncology case strong (plaintiff) / dangerous (defense)

• A documented abnormal result — imaging finding, tumor marker, positive screen — that was never communicated or acted on, with a clear interval of delay.
• A cancer caught at a stage where earlier diagnosis carried a materially better prognosis, supporting a strong loss-of-chance theory.
• A chemotherapy dosing or administration error with a clean operational causation chain (BSA miscalculation, wrong regimen, infusion error) and a documented toxic injury.
• A compliant, engaged patient whose record undercuts any patient-behavior defense.

What makes an oncology case weak (plaintiff) / defensible (defense)

• A pattern of documented non-adherence — missed appointments, declined imaging or biopsy — that drove the delay.
• A cancer whose biology made the outcome likely regardless of timing, so the lost window did not change the prognosis — the causation defense unique to delayed-cancer cases.
• A documented, individualized treatment decision with informed consent for known toxicities, framing an adverse event as a disclosed, accepted risk.
• Closed-loop follow-up in the record: abnormal results tracked, biopsies ordered, staging timely.

In oncology, causation is usually the decisive battleground, not breach. Even where a delay is obvious, the defense will argue that the cancer's stage or biology meant the patient's prognosis was the same regardless — the loss-of-chance question. The strongest plaintiff files and the most dangerous defense files are the ones where the expert can tie a specific lost window to a specific, quantifiable reduction in the chance of cure or survival. Building and pressure-testing that chain — and the qualifications of the oncology expert who will testify to it — is the work that decides these cases.

Bottom Line

Oncologists get sued infrequently, but the claims that arrive carry a severe tail driven by missed-cancer-diagnosis cases and chemotherapy errors. The dollars concentrate in delayed-diagnosis matters, where the damages are a lost cure or a shortened life, and the fight is almost always about causation and loss of chance rather than breach. The cannot-miss facts are the un-actioned abnormal result, the broken closed loop, and the dosing or administration error — weighed against any documented patient non-adherence and the cancer's underlying biology. Whether you are screening these cases for the plaintiff or defending them, grade the file on the strength of the loss-of-chance causation chain and the closed-loop record — not on the severity of the cancer alone.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all 70 specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →